10-Q: Septerna Reports First Quarter 2025 Financial Results and Highlights Novo Nordisk Collaboration

Septerna, Inc. announces its financial results for the first quarter of 2025 and highlights a new global collaboration with Novo Nordisk A/S.

Summary

• Septerna, Inc., a biotechnology company, reported a net loss of $21.5 million for the three months ended March 31, 2025, compared to a net loss of $14.2 million for the same period in 2024.
• The company's revenue for the quarter was $0.2 million, primarily from research services provided to Vertex Pharmaceuticals.
• Research and development expenses increased to $19.3 million, driven by higher direct costs associated with clinical and preclinical programs.
• General and administrative expenses rose to $6.9 million, mainly due to increased legal and consulting fees related to being a public company.
• As of March 31, 2025, Septerna had $398.2 million in cash, cash equivalents, and marketable securities.
• The company believes its current financial resources will be sufficient to fund operations for at least 12 months.
• Septerna entered into a global collaboration and license agreement with Novo Nordisk A/S in May 2025 to develop oral small molecule therapies for metabolic-related diseases.
• The Novo Nordisk collaboration includes a $195.0 million upfront payment and potential milestone payments exceeding $2.2 billion, plus tiered royalties on global product sales.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive; while the company reported a larger net loss, the collaboration with Novo Nordisk and strong cash position provide a positive outlook.

Positives

• Septerna has a strong cash position of $398.2 million as of March 31, 2025.
• The collaboration with Novo Nordisk provides significant upfront funding and potential future revenue through milestone payments and royalties.
• The company's Native Complex Platform is being leveraged for multiple research and development programs.
• The company believes its current financial resources will be sufficient to fund operations for at least 12 months.

Negatives

• Septerna incurred a net loss of $21.5 million for the three months ended March 31, 2025.
• The company has an accumulated deficit of $139.9 million as of March 31, 2025.
• The company's revenue is currently limited to research services and is not yet generating revenue from product sales.
• The company discontinued the SEP-786 clinical study in February 2025.

Risks

• The company is subject to risks inherent in operating an early-stage biotechnology business.
• The company's ability to generate product revenue depends on the successful development and commercialization of product candidates.
• The company will require substantial additional funding to further develop its product candidates and support its continuing operations.
• Unfavorable global economic conditions, political instability and geopolitical events could adversely affect the company's business, financial condition, stock price, and results of operations.
• Disruptions at the FDA and other government agencies caused by reduction in staffing, funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.

Future Outlook

Septerna expects to continue to incur net losses for the foreseeable future and will require substantial additional funding to further develop its product candidates and support its continuing operations; the anticipated upfront payment from the Collaboration Agreement is expected to significantly extend our prior cash runway guidance of early 2028, and updated guidance will be provided following the closing of the Collaboration Agreement.

Industry Context

Septerna's focus on GPCR-targeted therapies aligns with a growing interest in this area within the pharmaceutical industry, as GPCRs are involved in a wide range of diseases; the collaboration with Novo Nordisk, a major player in metabolic diseases, validates Septerna's technology and approach.

Comparison to Industry Standards

• Septerna's approach to GPCR drug discovery using its Native Complex Platform is innovative compared to traditional methods.
• Other companies in the GPCR space include structure-based drug design companies such as Schrödinger and Relay Therapeutics, but Septerna's platform focuses on replicating the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale.
• The $195 million upfront payment from Novo Nordisk is a significant deal, comparable to other major pharmaceutical collaborations in early-stage drug discovery.
• Comparable companies include those developing therapies for endocrinology, immunology and inflammation, and metabolic diseases.

Related Party Transactions

• In August 2021, the Company entered into a service agreement (the TRV service agreement) with Third Rock Ventures, LLC (TRV), a holder of more than 5% of the Company's outstanding capital stock, under which TRV provides consulting services to the Company.

Stakeholder Impact

• Shareholders: The collaboration with Novo Nordisk is a positive development, but the increased net loss may be a concern.
• Employees: The company is expanding its headcount to support business growth and research and development programs.
• Customers: The company is focused on developing novel oral small molecule medicines for patients with significant unmet needs.
• Suppliers: The company relies on third-party contract manufacturing organizations (CMOs) to manufacture and supply its preclinical and clinical materials.

Next Steps

• Advance a next-generation oral small molecule PTH1R agonist from our PTH1R program toward clinical development.
• Advance SEP-631 (MRGPRX2) into clinical development.
• Continue to advance other programs in our pipeline.
• Close the Collaboration Agreement with Novo Nordisk.

Key Dates

Keywords

GPCR, Novo Nordisk, Collaboration, Metabolic Diseases, Financial Results, Septerna, Biotechnology, Research and Development